Pharma BD Deal Intelligence

Laboratoires Théa / Iolyx Therapeutics, Inc.

2025 · Licensing/Option · $280M · Complete

Iolyx Therapeutics granted Laboratoires Théa exclusive worldwide development and commercialization rights, excluding Asia, to ILYX-002 for the treatment of ocular surface disease including autoimmune-associated dry eye disease. Iolyx is eligible for up to $280 million in clinical, regulatory and commercial milestones, tiered royalties of up to 21% on net sales, and reimbursement of ILYX-002 R&D expenses. Iolyx concurrently secured Series B financing for its retinal pipeline.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals